Monoclonal antibody Leu-22 (L60) permits the demonstration of some neoplastic T cells in routinely fixed and paraffin-embedded tissue sections.
Monoclonal antibody Leu-22 (L60) detects a T cell-associated antigen which is stably expressed in routinely fixed and paraffin-embedded tissue sections. We investigated the utility of monoclonal antibody Leu-22 to immunophenotype routinely processed lymphoid neoplasms by determining its reactivity in 105 archival pathologic specimens of lymphoid neoplasia that had been previously immunophenotyped by standard cell suspension and frozen tissue section techniques. Monoclonal antibody Leu-22 reacted with 69% of T cell non-Hodgkin's lymphomas (NHLs), including cases belonging to each of the major clinicopathologic categories, and with 22% of B cell NHLs, but did not react with the Reed-Sternberg (RS) cells of Hodgkin's disease (HD). We concluded that monoclonal antibody Leu-22 reacts preferentially but not exclusively with T cell NHLs. Therefore, we performed parallel analyses of the same 105 cases with monoclonal antibodies leukocyte common antigen (LCA), Leu-M1, LN1, and LN2, which detect various paraffin-resistant antigens, and of 80 of these cases with monoclonal antibody UCHL1, which detects a paraffin-resistant T cell-associated antigen. UCHL1 reacted with 61% of the T cell NHLs studied. Sixty-nine percent of T cell NHLs expressed the LCA+, Leu-22+ or Leu-M1+, LN1- phenotype and 47% of B cell NHLs expressed the LCA+, Leu-22-, Leu-M1-, LN1+ phenotype. These phenotypes had a false-positive rate of only 7%. The substitution of UCHL1 for Leu-22 or the combined use of UCHL1 and Leu-22 in this panel did not improve our ability to correctly predict the T cell phenotype of these lymphoid neoplasms. LN1 and LN2 reacted with 13% and 56% of T cell NHLs, respectively, and LN2 reacted with RS cells in 85% of cases of HD. In summary, our results demonstrate that the judicious use of monoclonal antibody Leu-22 in combination with other selected commercially available monoclonal antibodies permits the determination of the B cell or T cell origin of a high proportion of NHLs, and is helpful in the differential diagnosis between HD and NHL among cases that have been routinely fixed and paraffin-embedded.
Wieczorek
R
R
Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, NY 10032.
Buck
D
D
Bindl
J
J
Knowles
D M
DM
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation / Q000032:analysis; D001402:B-Lymphocytes / Q000032:analysis; D003937:Diagnosis, Differential; D006649:Histocompatibility Antigens / Q000032:analysis; D006689:Hodgkin Disease / Q000032:analysis / Q000473:pathology*; D006801:Humans; D007124:Immunoenzyme Techniques; D017493:Leukocyte Common Antigens; D008228:Lymphoma, Non-Hodgkin / Q000032:analysis / Q000473:pathology*; D008562:Membrane Glycoproteins / Q000032:analysis; D013601:T-Lymphocytes / Q000032:analysis
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D006649:Histocompatibility Antigens; D008562:Membrane Glycoproteins; D017493:Leukocyte Common Antigens